ArticleJournal of diabetes research2014
Plasma gelsolin levels decrease in diabetic state and increase upon treatment with F-actin depolymerizing versions of gelsolin.
Article in Journal of diabetes research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Integrated approaches to target nuclear receptors for managing the co-morbidity of tuberculosis and diabetes.Frontiers in immunology · 2026Article
- Inert Gas Mild Pressure Action on Healthy Humans: The "IPA" Study.International journal of molecular sciences · 2024Article
- Elevations of Extracellular Vesicles and Inflammatory Biomarkers in Closed Circuit SCUBA Divers.International journal of molecular sciences · 2023Article
- Plasma gelsolin levels are associated with diabetes, sex, race, and poverty.Journal of translational medicine · 2023Article
- Blood-Borne Microparticles Are an Inflammatory Stimulus in Type 2 Diabetes Mellitus.ImmunoHorizons · 2023Article
- Combining mass spectrometry and machine learning to discover bioactive peptides.Nature communications · 2022Article
- Proteomics Studies in Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2022Article
- Remission of Diabetes Following Bariatric Surgery: Plasma Proteomic Profiles.Journal of clinical medicine · 2021Article
- Plasma gelsolin modulates the production and fate of IL-1β-containing microparticles following high-pressure exposure and decompression.Journal of applied physiology (Bethesda, Md. : 1985) · 2021Article
- Proteomic and Structural Manifestations of Cardiomyopathy in Rat Models of Obesity and Weight Loss.Frontiers in endocrinology · 2021Article
- Regulation of Mitochondrial Function by the Actin Cytoskeleton.Frontiers in cell and developmental biology · 2021Review
- Deciphering the Plasma Proteome of Type 2 Diabetes.Diabetes · 2020Article
- Article
- Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection.Cell systems · 2020Article
- Systemic Proteome Alterations Linked to Early Stage Pancreatic Cancer in Diabetic Patients.Cancers · 2020Article
- Plasma gelsolin levels in patients with psoriatic arthritis: a possible novel marker.Clinical rheumatology · 2020Article
- Antioxidant and Wound Healing Property of Gelsolin in 3T3-L1 Cells.Oxidative medicine and cellular longevity · 2020Article
- iTRAQ plasma proteomics analysis for candidate biomarkers of type 2 incipient diabetic nephropathy.Clinical proteomics · 2019Article
- Protective effects of gelsolin in acute pulmonary thromboembolism and thrombosis in the carotid artery of mice.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study aims to map plasma gelsolin (pGSN) levels in diabetic humans and mice models of type II diabetes and to evaluate the efficacy of gelsolin therapy in improvement of diabetes in mice. We report that pGSN values decrease by a factor of 0.45 to 0.5 in the blood of type II diabetic humans and mice models. Oral glucose tolerance test in mice models showed that subcutaneous administration of recombinant pGSN and its F-actin depolymerizing competent versions brought down blood sugar levels comparable to Sitagliptin, a drug used to manage hyperglycemic condition. Further, daily dose of pGSN or its truncated versions to diabetic mice for a week kept sugar levels close to normal values. Also, diabetic mice treated with Sitagliptin for 7 days, showed increase in their pGSN values with the decrease in blood glucose as compared to their levels at the start of treatment. Gelsolin helped in improving glycemic control in diabetic mice. We propose that gelsolin level monitoring and replacement of F-actin severing capable gelsolin(s) should be considered in diabetic care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.